<DOC>
	<DOCNO>NCT00614471</DOCNO>
	<brief_summary>This 3 arm study ass efficacy safety PEGASYS + entecavir combination therapy treatment-naive patient HBeAg positive chronic hepatitis B . Patients randomize receive 1 ) PEGASYS 180 microgram s.c./week 48 week , 2 ) PEGASYS 180 microgram s.c./week 48 week + entecavir 0.5mg p.o . daily week 13 week 36 3 ) entecavir 0.5mg p.o . daily 24 week + PEGASYS 180 microgram s.c./week week 21 68 . Treatment follow 24 week treatment-free follow . The anticipated time study treatment 3-12 month group 1 2 , 1-2 year group 3 , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Plus Entecavir Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>adult patient , 1865 year age ; HBsAg positive , HBeAg positive antiHBe negative least 6 month , antiHBs negative ; absence cirrhosis confirm liver biopsy previous 12 month . previous treatment chronic hepatitis B within previous 6 month ; antiviral , antineoplastic immunomodulatory treatment previous 6 month ; coinfection active hepatitis A , hepatitis C , hepatitis D HIV ; history evidence medical condition associate chronic liver disease viral hepatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>